Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%

Código QR

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%

Harvey B Dubiner1, Robert Noecker21Clayton Eye Center, Morrow, GA; 2Ophthalmic Consultants of Connecticut, Fairfield, CT, USABackground: The purpose of this study was to characterize intraocular pressure (IOP) reduction throughout the day with travoprost ophthalmic solution 0.004% dosed once daily i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dubiner HB, Noecker R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ab7ada755665479cb113ce24127ffb07
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado AS, et al.
Publicado: (2011)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis V, et al.
Publicado: (2018)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell JH, et al.
Publicado: (2014)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Douglas J Rhee, et al.
Publicado: (2008)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Michael J Miyashiro, et al.
Publicado: (2010)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
por: Costa VP, et al.
Publicado: (2012)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: David A Godfrey, et al.
Publicado: (2009)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
por: Inoue K, et al.
Publicado: (2012)

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
por: Quaranta L, et al.
Publicado: (2015)

Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
por: Perera SA, et al.
Publicado: (2016)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma
por: Yuya Nomura, et al.
Publicado: (2010)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
por: Andrea Russo, et al.
Publicado: (2009)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: J Charles Henry, et al.
Publicado: (2008)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
por: Moisseiev E,&nbsp;Lazar M, et al.
Publicado: (2012)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang XJ, et al.
Publicado: (2011)

Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects
por: Mizoue S, et al.
Publicado: (2014)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe CF, et al.
Publicado: (2012)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
por: Moisseiev E, et al.
Publicado: (2013)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano T, et al.
Publicado: (2016)

Intravenous paracetamol and intraocular pressure reduction: mannitol may also be involved
por: Allegaert K
Publicado: (2016)

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
por: Fung DS, et al.
Publicado: (2014)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu DI, et al.
Publicado: (2015)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
por: Anne J Lee, et al.
Publicado: (2008)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
por: Deshpande SS, et al.
Publicado: (2017)

Prevalence of increased intraocular pressure in patients with Graves’ ophthalmopathy and association with ophthalmic signs and symptoms in the north-west of Iran
por: Eslami F, et al.
Publicado: (2019)

The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model
por: Baklayan GA, et al.
Publicado: (2014)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis VM, et al.
Publicado: (2018)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Changes in axial length and choroidal thickness after intraocular pressure reduction resulting from trabeculectomy
por: Usui S, et al.
Publicado: (2013)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013)

PERSIANN-CCS-CDR, a 3-hourly 0.04° global precipitation climate data record for heavy precipitation studies
por: Mojtaba Sadeghi, et al.
Publicado: (2021)

Influence of container structures and content solutions on dispensing time of ophthalmic solutions
por: Keiji Yoshikawa, et al.
Publicado: (2010)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Yelda Buyru &Ouml;zkurt, et al.
Publicado: (2009)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Sophia K Mirza, et al.
Publicado: (2010)